Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics and Safety of ABT-493 and ABT-530 in Subjects With Normal and Impaired Renal Function

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria: All Subjects~* Females must have negative results for pregnancy tests performed:~  * At Screening on a urine specimen, and~ * On a serum sample obtained on Study Day -2 (prior to dosing).~* Body Mass Index (BMI) is ≥ 18 to ≤ 38 kg/m2, inclusive.~* Body Weight \> 50 kg.~Subjects with Normal Renal Function~In addition to the main inclusion criteria above for all subjects, the following criteria must be met for subjects with normal renal function enrolled in Group 5:~* Judged to be in general good health based upon the results of a medical history, physical examination, and 12-lead electrocardiogram (ECG).~* At screening, estimated GFR (by MDRD equation) should be ≥ 90 mL/min/1.73 m2.~Subject with Renal Impairment~In addition to the main inclusion criteria for all subjects, the following criteria must be met for all subjects with renal impairment enrolled in Groups 1, 2, 3, 4 and 6:~* Judged to be in stable condition and acceptable for study participation based upon the results of a medical history, physical examination, laboratory profile and ECG.~* Presence of chronic renal impairment as indicated by medical history and a screening estimated GFR (by MDRD equation) \< 90 mL/min/1.73 m2.~* Subjects with ESRD undergoing hemodialysis should have been receiving dialysis for at least 1 month.~Exclusion Criteria: - History of significant sensitivity to any drug.~* Pregnant or breastfeeding female.~* Recent (6-month) history of drug or alcohol abuse.~* Positive test result for hepatitis A virus immunoglobulin M (HAV-IgM), hepatitis B surface antigen (HBsAg) or hepatitis C virus antibody (HCV Ab) or HIV antibodies (HIV Ab). Negative HIV status will be confirmed at Screening and the results will be maintained confidentially by the study site.~* Subjects on strict vegetarian diet.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Group 1 - Mild Renal Impairment (Type: EXPERIMENTAL): Subjects with mild renal impairment. eGFR (by MDRD equation) range 60 - 89 mL/min/1.73 m2 as determined at Screening.
- Group 2 - Moderate Renal Impairment (Type: EXPERIMENTAL): Subjects with moderate renal impairment. eGFR (by MDRD equation) range 30 - 59 mL/min/1.73 m2 as determined at Screening.
- Group 3 - Severe Renal Impairment (Type: EXPERIMENTAL): Subjects with severe renal impairment. eGFR (by MDRD equation) range 15 - 29 mL/min/1.73 m2 as determined at Screening.
- Group 4 - End Stage Renal Disease, Not Yet on Dialysis (Type: EXPERIMENTAL): Subjects with end stage renal disease, not yet on dialysis. eGFR (by MDRD equation) range \< 15 mL/min/1.73 m2 as determined at Screening.
- Group 5 - Normal Renal Function (Type: EXPERIMENTAL): Subjects with normal renal function. eGFR (by MDRD equation) range ≥ 90 mL/min/1.73 m2 as determined at Screening.
- Group 6 - End Stage Renal Disease, Requiring Dialysis. (Type: EXPERIMENTAL): Subjects with end stage renal disease, requiring dialysis. eGFR (by MDRD equation) \< 15 mL/min/1.73 m2 as determined at Screening.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete